Back
Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/18/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/18/2021.
Displaying: 415 trials in your specialties ()
View trials across your selected specialties

Study of Azacitidine and Durvalumab in Advanced Solid Tumors

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Microsatellite Stable Colorectal Carcinoma, Platinum Resistant Ep...
View Full Trial
INTERVENTION

Drug: Azacitidine, Drug: Durvalumab

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Brief Summary

This is a phase 2 study of investigational drug, durvalumab given in combination with azacitidine (CC-486). The main purpose of this phase 2 study is to assess the antitumor activity of azacitidine in combination with durvalumab patients with microsatellite stable colorectal carcinoma (MSS-CRC), platinum resistant epithelial ovarian cancer type II (PR-OC), and estrogen receptor positive and HER2 negative breast cancer.

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

  • Status
    Recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Previously Untreated Acute Myeloid Leukemia
View Full Trial
INTERVENTION

Biological: Samalizumab (BAML-16-001-S1), Biological: BI 836858 (BAML-16-001-S2), Other: Laboratory Biomarker Analysis, Drug: Daunorubicin (BAML-16-001-S1), Drug: Cytarabine (BAML-16-001-S1), Drug: Azacitidine (BAML-16-001-S2), Drug: AG-221 (BAML-16-001-S3), Drug: Azacitidine (BAML-16-001-S3), Drug: Entospletinib (BAML-16-001-S4), Drug: Azacitidine (BAML-16-001-S4), Drug: Entospletinib (BAML-16-001-S5), Drug: Decitabine (BAML-16-001-S5), Drug: Entospletinib (BAML-16-001-S6), Drug: Daunorubicin (BAML-16-001-S6), Drug: Cytarabine (BAML-16-001-S6), Drug: Pevonedistat (BAML-16-001-S9), Drug: Azacitidine (BAML-16-001-S9), Drug: AG-120 (BAML-16-001-S16), Drug: Azacitidine (BAML-16-001-S16), Drug: Gilteritinib (BAML-16-001-S8), Drug: Decitabine (BAML-16-001-S8), Drug: Acalabrutinib (BAML-16-001-COV1), Other: Standard Therapy (BAML-16-001-COV1), Drug: AZD5153 (BAML-16-001-S10), Drug: Venetoclax (BAML-16-001-S10), Drug: TP-0903 (BAML-16-001-S14), Drug: Decitabine (BAML-16-001-S14)

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Mayo Clinic Arizona, Phoenix, Arizona, United States

Brief Summary

This screening and multi-sub-study Phase 1b/2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloid leukemia will determine which sub-study, within this protocol, a participant will be assigned to evaluate investigational therapies or combinations with the ultimate goal of advancing new targeted therapies for approval. The study also includes a marker negative sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies.

Azacitidine, Durvalumab, and Tremelimumab in Recurrent and/or Metastatic Head and Neck Cancer Patients

  • Status
    Recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Head and Neck Cancer
View Full Trial
INTERVENTION

Drug: Azacitidine, Drug: Durvalumab, Drug: Tremelimumab

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Massachusetts General Hospital, Boston, Massachusetts, United States

Brief Summary

This is a non-randomized, open-label, Phase Ib/II study to assess the safety and efficacy of azacitidine, durvalumab (MEDI4736), and tremelimumab combination therapy in the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) who have progressed during or after treatment with anti-PD-1, anti-PD-L1, or anti-CTLA-4 monotherapy for recurrent and/or metastatic disease. The clinical trial is studying drugs that can boost the participant's immune system against the cancer cells as a possible treatment for head and neck cancer. The study interventions involved in this study are: - Azacitidine (Vidaza) - Durvalumab (MEDI4736) - Tremelimumab

Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adul...
View Full Trial
INTERVENTION

Drug: Sirolimus, Drug: Azacitidine

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Jefferson Health NJ Division (Kennedy Hospital), Sewell, New Jersey, United States

Brief Summary

This phase II trial studies how well sirolimus and azacitidine works in treating patients with high-risk myelodysplastic syndrome or recurrent acute myeloid leukemia. Sirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Sirolimus and azacitidine may kill more cancer cells.

Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine

  • Status
    Active, not recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomo...
View Full Trial
INTERVENTION

Drug: oral rigosertib, Drug: Azacitidine

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

Brief Summary

This study, is a Phase I/II clinical trial in three parts: Phase I Dose Escalation, Phase II, Part 1 RPTD Cohort, and Phase II, Part 2 Expansion. The first two parts have been completed. The Phase II, Part 2 Expansion will assess if treatment with rigosertib in combination with azacitidine, has measurable effects in patients with myelodysplastic syndrome (MDS). Safety of patients is an objective throughout all parts of the study.

Efficacy and Safety Evaluation of IBI188 in Combination With Azacitidine in Treatment of Patients With Acute Myeloid Leukemia

  • Status
    Recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Acute Myeloid Leukemia
View Full Trial
INTERVENTION

Drug: IBI188, Drug: Azacitidine

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Brief Summary

The study is to evaluate safety, tolerability and composite CR of IBI188 plus azacitidine in acute myeloid leukemia

N/A

  • Status
    Not yet recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Not provided
View Full Trial
INTERVENTION

Not provided

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Brief Summary

N/A

Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

  • Status
    Recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplas...
View Full Trial
INTERVENTION

Drug: Azacitidine, Drug: Venetoclax

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

M D Anderson Cancer Center, Houston, Texas, United States

Brief Summary

This phase I/II trial investigates the side effects and best dose of venetoclax when given together with azacitidine and to see how well it works in treating patients with high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia that has come back (relapsed) or has not responded to treatment (refractory). Venetoclax may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax and azacitidine together may help to control myelodysplastic syndrome or chronic myelomonocytic leukemia.

Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine, Abraxane, Gemcitabine)

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Pancreatic Cancer
View Full Trial
INTERVENTION

Drug: oral azacitidine, Other: Observation, Drug: First-line chemotherapy after recurrence

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Johns Hopkins, Baltimore, Maryland, United States

Brief Summary

To improve progression free survival in high risk patients with resected pancreatic adenocarcinoma who have node positive disease, margin positive disease, and/or elevation in CA 19-9 treated with CC-486 (oral azacitidine) as compared to observation after completion of adjuvant therapy.

Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza)

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Acute Myelocytic Leukemia, Myelodysplastic Syndrome
View Full Trial
INTERVENTION

Drug: Azacitidine

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Universitätsklinikum Bonn, Bonn, Germany

Brief Summary

Assessment of efficacy of azacitidine to prevent a relapse